about
Clozapine combined with different antipsychotic drugs for treatment resistant schizophreniaDiscontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs.Significant Effect of Valproate Augmentation Therapy in Patients With Schizophrenia: A Meta-analysis StudyNeuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophreniaOff-label use of sodium valproate for schizophreniaGenome-wide association study of treatment refractory schizophrenia in Han ChineseSensorimotor gating and clinical outcome following cognitive behaviour therapy for psychosis.Beyond dopamine: functional MRI predictors of responsiveness to cognitive behaviour therapy for psychosis.Synaptic proteins in the postmortem anterior cingulate cortex in schizophrenia: relationship to treatment and treatment response.Comparison of clozapine response for inpatients in the research setting versus routine clinical practiceFine-tuning of awake prefrontal cortex neurons by clozapine: comparison with haloperidol and N-desmethylclozapine.Patients with poor response to antipsychotics have a more severe pattern of frontal atrophy: a voxel-based morphometry study of treatment resistance in schizophrenia.Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.Antipsychotic Polypharmacy in Clozapine Resistant Schizophrenia: A Randomized Controlled Trial of Tapering Antipsychotic Co-treatment.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.Pharmacotherapy for treatment-resistant schizophrenia.Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review.Aripiprazole augmentation in patients with resistant obsessive compulsive disorder: a pilot study.Influence of 5-HT1A and 5-HTTLPR genetic variants on the schizophrenia symptoms and occurrence of treatment-resistant schizophreniaUnderstanding antipsychotic "atypicality": a clinical and pharmacological moving targetPharmacogenetics of antipsychotic-induced side effectsGlutamatergic neurometabolites in clozapine-responsive and -resistant schizophreniaMitochondria in the striatum of subjects with schizophrenia: relationship to treatment response.Priorities and standards in pharmacogenetic research.Emerging empirical evidence on the ethics of schizophrenia research.Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms.Current schizophrenia drugs: efficacy and side effects.Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?Dysfunctional Striatal Systems in Treatment-Resistant Schizophrenia.Genetic variation in BDNF is associated with antipsychotic treatment resistance in patients with schizophrenia.Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive.Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment.Adding or switching antipsychotic medications in treatment-refractory schizophrenia.Genomics and the future of pharmacotherapy in psychiatry.Clozapine underutilization and discontinuation in African Americans due to leucopenia.Cardiac-related findings at autopsy in people with severe mental illness treated with clozapine or risperidoneDoes the addition of a second antipsychotic drug improve clozapine treatment?Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia.Effectiveness of financial incentives to improve adherence to maintenance treatment with antipsychotics: cluster randomised controlled trial.
P2860
Q24240093-0521D3ED-399D-4C36-BD0D-70C1711B86D8Q25257471-74B21291-FC56-48EA-9695-72CF17A5DAD4Q26772965-30D77C24-FDCA-479E-A101-1E904D2362ECQ27026382-105B66FC-11E6-4CD6-9702-CC30E677FF89Q28541404-F0BCC7D3-E81F-46D1-9D3D-6C1ED2A6A780Q28943538-1C267B3B-531D-452D-B189-C5B528724AB4Q30470229-09132B89-F9FB-466B-A214-EF799457A086Q30483150-744067A4-8F87-4BE7-B3C8-BE381454421AQ33923576-A8007241-5669-4237-8CEF-8DAF5247E3D3Q33994937-8EB11698-397D-406E-AE65-D8CC1584277EQ34021750-01DF5934-5E67-4AAE-B4E6-146DF6FAC1D1Q34041815-77EAD219-12D1-46BF-B633-243098C39DE8Q34274859-26D6AD3E-7A23-4D7D-B785-46FD8A27ED39Q34338202-E6B4DCED-3223-4144-AD1C-FD7066377979Q34618937-BDC0AB0C-77BB-4D8B-A230-4B53EE0108DEQ34640811-A4CE9FB5-11ED-4E04-A708-CF7C4BBA6D10Q34879109-0E4414A5-16C7-4D82-926D-E4D0368D4B81Q34879435-A75B687F-349D-4331-8359-E00364F282B5Q35047082-71564902-F0D7-4ED7-8674-9737CCFC7630Q35136003-ABA027FB-BBA8-45C5-9CA1-841A3FB9B9D0Q35200831-CFCC5DD2-AC2C-42A2-AB6C-0821A773CF90Q35237129-CCFDC2A3-C7D4-4893-8D8E-FDC74804D211Q35626964-7C8AB4AC-768B-43E1-9195-0299A807765CQ35858324-893CD4C7-3A88-4CFE-8DA1-04C952E25B94Q36180606-65ED49B3-6510-4FF4-8156-5C3D1C3445BAQ36291530-29A908FE-55D2-4B25-BF73-AB90C05705D7Q36371727-D0D4B074-18CC-4A60-B882-77B0CE755844Q36488206-8A0C7054-942E-4CDA-BA3F-7339C078E12BQ36627988-FD2CD684-96A8-45BC-A76C-DE1129D7B24BQ36690658-1F6BE0DA-AF3E-4B0B-A8F6-A09ACDDD11E9Q36756159-12B9F146-A3E3-4343-BB0F-996E34C2EC96Q36817154-4FF7716C-F303-401E-BB81-7239CDE9E62FQ36838322-11E4D5DA-E967-45FE-ADF4-6ED3A6C40B27Q36905070-BC7067C3-9451-4C9E-B4F2-0B70984525FFQ36951758-E5F7DE3E-14E8-4A72-BBC8-ED95D95F14C0Q37076129-6ECBF6E6-EC6C-4335-A145-4994F1CDAC81Q37091444-264A2ACA-F303-48A9-A9AD-81535F33D1C4Q37147547-A2B2E892-24FA-40BB-8F32-6875C691F2B8Q37209442-9803A22A-EAE7-4545-857D-68FEC3FCFAD4Q37248219-301B885C-1F4B-4F67-A06B-05DAC45F7E24
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Management of treatment resistance in schizophrenia.
@ast
Management of treatment resistance in schizophrenia.
@en
Management of treatment resistance in schizophrenia.
@nl
type
label
Management of treatment resistance in schizophrenia.
@ast
Management of treatment resistance in schizophrenia.
@en
Management of treatment resistance in schizophrenia.
@nl
prefLabel
Management of treatment resistance in schizophrenia.
@ast
Management of treatment resistance in schizophrenia.
@en
Management of treatment resistance in schizophrenia.
@nl
P1476
Management of treatment resistance in schizophrenia.
@en
P2093
P304
P356
10.1016/S0006-3223(01)01271-9
P407
P577
2001-12-01T00:00:00Z